Related Experiment Video

Updated: Jan 10, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.0K

Lipid lowering therapies in chronic kidney disease: A call to action

Jaime Mazón-Ruiz1, David Arroyo2, Marina de Cos3

  • 1Nephrology Department, Hospital Carmen y Severo Ochoa, Cangas del Narcea, Spain.

Atherosclerosis
|November 21, 2025
PubMed

Insights

Patients with chronic kidney disease (CKD) have high cardiovascular risk but are undertreated with lipid-lowering therapies (LLT). More research is needed to optimize dyslipidemia management in this population.

Area of Science:

  • Nephrology
  • Cardiology
  • Clinical Trials

Background:

  • Atherosclerotic cardiovascular disease (ASCVD) is the primary cause of mortality in chronic kidney disease (CKD) patients.
  • CKD patients experience higher cardiovascular event rates than the general population.
  • Lipid-lowering therapies (LLT) are underutilized in CKD patients for cardiovascular event prevention.

Purpose of the Study:

  • To systematically review the evidence on LLT for ASCVD prevention in CKD patients.
  • To identify gaps in randomized clinical trials (RCTs) regarding CKD patient inclusion.
  • To highlight the need for tailored lipid management strategies in CKD.

Main Methods:

  • Systematic review of existing literature.
  • Analysis of CKD patient representation in RCTs evaluating LLT.
  • Assessment of current treatment guidelines based on available evidence.

Main Results:

  • CKD patients are significantly underrepresented in RCTs for LLT.
  • Current treatment recommendations for dyslipidemia in CKD often rely on extrapolated data.
  • Evidence gaps exist for effective lipid management in this high-risk group.

Conclusions:

  • Dedicated clinical trials are crucial to address the specific lipid management needs of CKD patients.
  • Optimizing LLT in CKD populations is essential for reducing cardiovascular risk.
  • Further research is needed to improve cardiovascular outcomes in CKD patients through targeted interventions.

Keywords:
AtherosclerosisCardiovascular riskChronic kidney diseaseDyslipidemiaLipoproteins

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.5K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.0K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
326
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
531
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
549
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
284
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301